Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3.
about
The shaping of modern human immune systems by multiregional admixture with archaic humansNK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell EngraftmentNK cell function and receptor diversity in the context of HCV infectionEffects of Peptide on NK cell-mediated MHC I recognitionA Coevolutionary Arms Race between Hosts and Viruses Drives Polymorphism and Polygenicity of NK Cell Receptors.KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A * 11 while diminishing avidity for HLA-CMutational and Structural Analysis of KIR3DL1 Reveals a Lineage-Defining Allotypic Dimorphism That Impacts Both HLA and Peptide SensitivityKIR-HLA genotypes in HIV-infected patients lacking immunological recovery despite effective antiretroviral therapyCo-evolution of human leukocyte antigen (HLA) class I ligands with killer-cell immunoglobulin-like receptors (KIR) in a genetically diverse population of sub-Saharan AfricansEnrichment of variations in KIR3DL1/S1 and KIR2DL2/L3 among H1N1/09 ICU patients: an exploratory studyCoevolution of killer cell Ig-like receptors with HLA-C to become the major variable regulators of human NK cellsMeiotic recombination generates rich diversity in NK cell receptor genes, alleles, and haplotypesCanonical and Cross-reactive Binding of NK Cell Inhibitory Receptors to HLA-C Allotypes Is Dictated by Peptides Bound to HLA-C.The structure of the atypical killer cell immunoglobulin-like receptor, KIR2DL4.Can Selective MHC Downregulation Explain the Specificity and Genetic Diversity of NK Cell Receptors?Recruitment of activation receptors at inhibitory NK cell immune synapsesDonor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemiaNatural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR).NK cells in HIV-1 infection: evidence for their role in the control of HIV-1 infection.Human-specific evolution and adaptation led to major qualitative differences in the variable receptors of human and chimpanzee natural killer cellsHLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer ImmunotherapyChimpanzees use more varied receptors and ligands than humans for inhibitory killer cell Ig-like receptor recognition of the MHC-C1 and MHC-C2 epitopesHuman NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansionLow CD4+ T cell counts among African HIV-1 infected subjects with group B KIR haplotypes in the absence of specific inhibitory KIR ligands.Natural killer cell function and dysfunction in hepatitis C virus infection.Peptide antagonism as a mechanism for NK cell activation.KIR2DL2 enhances protective and detrimental HLA class I-mediated immunity in chronic viral infectionPrimate-specific regulation of natural killer cells.Significant association of KIR2DL3-HLA-C1 combination with cerebral malaria and implications for co-evolution of KIR and HLA.Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia.HIV-1 adaptation to NK-cell-mediated immune pressureMaternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2.Increased frequency and function of KIR2DL1-3⁺ NK cells in primary HIV-1 infection are determined by HLA-C group haplotypes.KIR diversity in Māori and Polynesians: populations in which HLA-B is not a significant KIR ligand.Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus.Fine-mapping of HLA associations with chronic lymphocytic leukemia in US populations.Allele-level haplotype frequencies and pairwise linkage disequilibrium for 14 KIR loci in 506 European-American individualsHLA-E-restricted cross-recognition of allogeneic endothelial cells by CMV-associated CD8 T cells: a potential risk factor following transplantation.Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection.Natural killer cell-based therapies.
P2860
Q22065603-1486DB46-35A7-44FF-8939-A2CDA4E4E270Q26765845-AF9DB3A9-7311-4B39-BECB-4D11D4B9D688Q26781537-1CD0BCBC-298B-448B-92AF-ECE8613439F2Q26822893-1A6CBA36-3EB5-44EC-B76B-5D5D4A3F8CD8Q27300206-90AAC9D5-7606-4AEB-9DB2-F94E0A2102A5Q27657994-C7A9CF49-1EEB-4FD2-AABB-C01C221755BEQ27681870-1D497799-999A-4047-8433-FD57B1B732A0Q28477797-3C72DFD0-021C-4112-9BF5-1A1E6D081FBCQ28534758-A5B14B4B-D6FC-4219-95F4-08AE7D05B683Q28740790-3DCCF2B6-75B0-4595-BA03-1273F546D404Q28743223-3945CE8C-4F7D-49F1-9D47-B97E2109DEDCQ28754594-494ECC7E-7A4A-4CA8-AB93-D2218527AED6Q30252783-A79C7785-15E6-4AA0-A1CA-5557094DE3E5Q30372604-01FB3C39-0EA4-425B-8422-5EF6655ED3FCQ30654514-544A80E5-66B9-4617-827B-5FC7521C3C16Q33372126-48E3FE83-95F0-42FB-9A38-DD8AFBCAF3EBQ33651178-FDA8BC0E-B034-48C3-B7CC-6DE12B4FA6DDQ33672480-0F4EA49F-09FE-461E-B517-2FBC33EEAA89Q33741498-43C597E3-4FC7-4AC8-8B76-FF466F7E4A37Q33747569-A9D9C5F4-E2E5-42B8-9A45-84ADBBA2B109Q33785744-FA9E67E5-BBC1-47CC-904D-2AC254FFBED3Q33789518-967BC6E8-0065-40B3-AC72-E80A28006476Q33816097-B988F141-F7EE-45AE-8624-440B92832AC3Q33828392-CD8E06A4-8068-4FF4-8B72-FAAF3D596C37Q33892695-94C8507E-5E4F-4CEA-808C-7ED5984CFAA9Q33933479-4CA523F4-7EAB-41B0-A89C-051AAF973F48Q34055276-0A696F15-2DBD-42E4-978F-1E572D795495Q34064807-9DB168D5-DB08-4975-9AFD-356927698CC7Q34192841-2132707C-FCEF-4BF8-9374-9CF0F192229DQ34193507-6709170F-232B-45C9-B0E5-B278AA16FBF3Q34205851-FF88AA03-4AA1-4C31-BC7A-BD506BAC9EB9Q34245469-3D4F7629-AB73-4F78-848A-8B362B044261Q34339253-2E2874D7-A412-4EEF-87E4-DF34AF52E2E2Q34345310-07D3E69B-AD57-435B-92C1-6D3D95D9D1E1Q34365617-38360A72-777E-4881-94B7-CA4B435223D7Q34398369-F492BA47-38E6-4D3E-9B54-B0636413E4E4Q34471812-56BFA0DA-32EA-4C74-A240-9B35A8099015Q34506165-D8904B40-9B99-4307-BE13-728AD74AA4FDQ34804539-F6EB7A8A-7737-4754-A69D-1668FA9290FCQ34988727-52DABA70-48BE-4971-A1FE-E8EFED91AB39
P2860
Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Synergistic polymorphism at tw ...... ceptor for HLA-C than KIR2DL3.
@ast
Synergistic polymorphism at tw ...... ceptor for HLA-C than KIR2DL3.
@en
type
label
Synergistic polymorphism at tw ...... ceptor for HLA-C than KIR2DL3.
@ast
Synergistic polymorphism at tw ...... ceptor for HLA-C than KIR2DL3.
@en
prefLabel
Synergistic polymorphism at tw ...... ceptor for HLA-C than KIR2DL3.
@ast
Synergistic polymorphism at tw ...... ceptor for HLA-C than KIR2DL3.
@en
P2093
P3181
P1476
Synergistic polymorphism at tw ...... ceptor for HLA-C than KIR2DL3.
@en
P2093
Achim K Moesta
Makoto Yawata
Michael Gleimer
Nobuyo Yawata
Paul J Norman
Peter Parham
P304
P3181
P356
10.4049/JIMMUNOL.180.6.3969
P407
P577
2008-03-01T00:00:00Z